IntegraGen Partners with CRUK to Validate miRNA Marker for Colorectal Cancer Drug Response | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics firm IntegraGen said today that it is collaborating with Cancer Research UK to validate a microRNA as a biomarker for the prediction of progression-free survival in patients with metastatic colorectal cancer who have received anti-EGFR therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.